4David M, Hie-Woul H, Maria B, et al. Significant clinical improvement following the addition of adefovir dipivoxil to lamivudine in decompensated Patients with YMDD variant HBV and a reduced response to lamivudine. Hepatology ,2002,36:625.
二级参考文献14
1Balzarini, J., Z. Hao, P. Herdewijn, et al . Intracellular metabolism and mechanism of antiretrovirus action of 9- (2-phosphonylmethoxyethyl ) adenine, a potent anti - human immunodeficiency virus compound [ J] . Proc. Natl. Acad. Sci.USA, 1991, 88:1499.
2Seigneres, B., S. Aguesse- Germon, C. Pichoud, et al . Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo [J] . J. Hepatol. 2001, 34:114.
3Barditch - Crovo P, Toole J, Hendrix CW, et al. Anti - human immunodeficiency virus activity and pharmacokinetics of adefovir depivoxil in HIV - infected patients [J] . J Infec Dis. 1997, 176(2): 406.
5Cullen JM, Li DH, Brown C, et al. Antiviral efficacy and pharmacokinetics of adefovir dipivoxol in chronically woodchuck hepatitis virus- infected woodchucks [ J ] .Antimicrob Agent Chemother. 2001, 45 (10): 2740.
6Nicoll AJ, Colledge DL, Toole JJ, et al. Inhibition of duck hepatitis B virus replication by 9- (2- phosphonylmethoxyethyl) adenine,an acryclic phosphonate nucleoside analogue [ J] . Antimicrob Agent Chemother. 1998, 42:3130.
7FDA Advisory Committee Briefing Document. Adefovir DipivoxilFor the Treatment of Chronic Hepatitis B. NDA 21 -449:77.
8John M, Cullen, Daniel H. Li, et al. Antiviral Efficacy and Pharmacokinetics of Oral Adefovir Dipivoxil in Chronically Woodchuck Hepatitis Virus- Infected Woodchucks [ J ]Antimicrobial Agents and Chemotherapy, 2001, 45 (10): 2740.
9Shaw JP, Louie MS, Krishnamurthy VV, et al. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats [ J ] . Drug Metab Dispos, 1997, 25 (3): 362.
10Gilson R J, Chopra KB, Newell AM, et al. A placebo- controlled phase Ⅰ/Ⅱstudy of adefovir dipivoxil in patients with chronic hepatitis B virus infection [J] . J Viral Hepat , 1999, 6:387.
6ZARUBA K, GROB PJ, BOLLA K. Thymopentin as adjuvant therapy to hepatitis B vaccination in formerly non-or hyporespond- ing hemodialysis patients [ J ]. Surv lmmunol Res, 1985,4 ( Suppl 1) :102 - 106.
7GROB PJ, BINSWANGER U, BLUMBERGA, etal. Thymo- pentin as adjuvant to hepatitis B vaccination. Results from three double-blind studies[ J]. Sarv lmmunol Res, 1985, 4 (Suppl 1) :S107 - $115.
